Non-dilated left ventricular cardiomyopathy (NDLVC) represents a newly defined entity where patients develop life-threatening ventricular arrhythmias despite normal ventricular dimensions, creating urgent need for risk stratification beyond ejection fraction alone.
The Study
A retrospective cohort of 337 NDLVC patients without prior major arrhythmic events from two large centers underwent comprehensive diagnostic workup including cardiac magnetic resonance (CMR), endomyocardial biopsy, and genetic testing, establishing the first systematic predictors of first major arrhythmic event (MAE), i.e., sustained ventricular tachycardia, ventricular fibrillation, or appropriate implantable cardioverter-defibrillator (ICD) therapy, over 60-month follow-up. The results were published in the European Heart Journal. 
Patient Characteristics and Event Rate
The cohort averaged 37 years old with 62% male predominance and mean LVEF 52±8%, where 79% exhibited late gadolinium enhancement (LGE) on baseline CMR. By 60 months, 51 patients (15%) experienced a first MAE, underscoring NDLVC's malignant potential despite preserved ventricular size and function.
The Six MAE Predictors Ranked by Strength
Multivariate analysis identified six independent predictors of first MAE, each contributing distinct risk magnitude. Myocardial inflammation (proven by biopsy/CMR) conferred the highest hazard with HR 15.7 (95% CI 6.1–40.3), representing inflammatory cardiomyopathy's arrhythmic substrate. Pathogenic variants in high-risk genes followed with HR 4.6 (95% CI 2.3–9.1), validating genotype-phenotype correlation in NDLVC. LVEF <45% significantly increased the risk (HR 5.5, 95% CI 2.7–11.0), while non-sustained VT (HR 3.1, 95% CI 1.7–5.6) and male sex (HR 2.4, 95% CI 1.3–4.4) provided incremental discrimination. Septal LGE pattern (HR 2.0, 95% CI 1.0–4.0) edged statistical significance while ring-like LGE trended toward risk (HR 1.3).
External Validation Confirms Model Performance
A validation cohort of 216 NDLVC patients from 11 European centers replicated the predictor profile, achieving Uno's C-index 0.81 (95% CI 0.75–0.88), establishing transportability across diverse populations and imaging/genetic platforms.
Novel Risk Score Derived
Investigators synthesized these predictors into a composite risk score enabling systematic NDLVC risk stratification. The model integrates clinical (sex, NSVT), imaging (LGE pattern, LVEF), genetic, and histopathologic signals, overcoming ejection fraction's limitations in non-dilated cardiomyopathy.
Why LGE Pattern Matters
Septal LGE (HR 2.0) identifies conduction system scarring prone to reentry circuits, while ring-like mid-wall fibrosis (HR 1.3) signals diffuse arrhythmogenic substrate. These CMR textures guide ICD decision-making beyond scar burden alone.
The Inflammation Bombshell
Myocardial inflammation's HR 15.7 dwarfs all other predictors, positioning biopsy/CMR confirmation as mandatory in suspected inflammatory NDLVC. 
For the Frontline Clinician
NDLVC suspicion? The clinicians may order comprehensive CMR (LGE pattern critical), genetic panel (high-risk variants), and consider biopsy if inflammation suspected. They may apply the 6-factor risk score rather relying on LVEF 52% reassurance.
Bottom line: NDLVC patients gain their first validated risk calculator integrating sex, arrhythmia history, function, fibrosis pattern, genotype, and inflammation.